<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717947</url>
  </required_header>
  <id_info>
    <org_study_id>HCB/2019/1109</org_study_id>
    <nct_id>NCT04717947</nct_id>
  </id_info>
  <brief_title>Interval Between Neoadjuvant Therapy and Surgery in the Treatment of Locally Advanced Rectal Cancer (CRONOS)</brief_title>
  <acronym>CRONOS</acronym>
  <official_title>Interval Between Neoadjuvant Therapy and Surgery in the Treatment of Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Complejo Hospitalario Universitario de Santiago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Sant Joan Despí Moisès Broggi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Son Espases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluate the response of rectal cancer to neoadjuvant therapy and classify&#xD;
      the response according to specific periods of time after the end of neoadjuvant treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the treatment of locally advanced rectal cancer, an optimal interval between neoadjuvant&#xD;
      therapy and surgery might improve oncological outcomes. Besides, those patients who achieve a&#xD;
      good response might benefit from active surveillance, avoiding surgical comorbidities. This&#xD;
      optimal interval is yet to be defined. This study will aim to better define the role of time&#xD;
      interval between the end of neoadjuvant therapy (NAT) and TME in Spanish regions, together&#xD;
      with analyzing the importance of restaging MRI and define the basis for implementing a &quot;watch&#xD;
      and wait&quot; protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">June 25, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response</measure>
    <time_frame>2000-2019</time_frame>
    <description>Grade as complete</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circumferential margin (CRM)</measure>
    <time_frame>2000-2019</time_frame>
    <description>Described as free (CRM &gt;1 mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distal resection margin (DRM)</measure>
    <time_frame>2000-2019</time_frame>
    <description>Described as free (DRM &gt;1 mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of the specimen</measure>
    <time_frame>2000-2019</time_frame>
    <description>Described as complete or incomplete</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">911</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Neoadjuvant Therapy</condition>
  <arm_group>
    <arm_group_label>Short interval group</arm_group_label>
    <description>≤ 8weeks between the end of neoadjuvant therapy and surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate interval group</arm_group_label>
    <description>&gt; 8 and ≤ 12 weeks between the end of neoadjuvant therapy and surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long interval group</arm_group_label>
    <description>&gt; 12 weeks between the end of neoadjuvant therapy and surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interval between NAT and surgery</intervention_name>
    <description>Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.</description>
    <arm_group_label>Intermediate interval group</arm_group_label>
    <arm_group_label>Short interval group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This was a national multicentre retrospective cohort study. Participating centres are&#xD;
        tertiary referral hospitals from different Spanish regions, which agreed to enter&#xD;
        information in a standardized database, of all patients in their institute who had&#xD;
        biopsy-confirmed rectal adenocarcinoma and had received neoadjuvant therapy. All patients&#xD;
        with low, mid and high rectal cancer (0-15 cm from the anal verge), at a clinical stage&#xD;
        IIA, IIB, IIIA, IIIB, IIIC (cT3/cT4, or cN1/cN2 with any cT, M0) will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients suitable for elective surgical resection of biopsy-confirmed rectal&#xD;
             adenocarcinoma (0-15 cm from the anal verge) determined by rectal cancer protocol&#xD;
             magnetic resonance imaging.&#xD;
&#xD;
          -  Patients treated with long-course neoadjuvant chemoradiotherapy (nCRT).&#xD;
&#xD;
          -  Patients treated with short-course radiotherapy with delayed surgery.&#xD;
&#xD;
          -  Clinical stage IIA, IIB, IIIA, IIIB, IIIC (cT3/cT4, or cN1/cN2 with any cT, M0)&#xD;
             determined by rectal cancer protocol magnetic resonance imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerance or contraindication to planned NAT.&#xD;
&#xD;
          -  Patients who have not finished NAT for any reason.&#xD;
&#xD;
          -  Patients with unknown cT or cM.&#xD;
&#xD;
          -  Tumors previously treated with local excision or with distant metastatic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Lacy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

